For the quarter ending 2026-03-31, NUVB had -$38,695K decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) | 5,397 | -36,592 | -55,792 | -112,243 |
| Stock-based compensation | 9,033 | 7,988 | 8,021 | 19,885 |
| Depreciation and amortization | 536 | 539 | 534 | 666 |
| Non-cash lease expense | -66 | -6 | -54 | 335 |
| Non-cash interest on revenue interest financing agreement | -5,079 | -5,017 | -4,855 | -266 |
| Amortization of debt issuance costs | 321 | 327 | 317 | 18 |
| Change in fair value of warrant liability | -2,865 | 1,127 | -612 | 297 |
| Amortization of premium and discounts on marketable securities | 839 | 1,188 | 1,287 | 2,809 |
| Realized loss (gain) on marketable securities | 8 | 3 | 0 | 2 |
| Net loss on disposal of fixed assets | - | - | -30 | - |
| Net loss on disposal of property and equipment | - | 1 | - | -34 |
| Unrealized foreign currency transaction (loss) gain | 21 | 670 | 210 | 205 |
| Acquired in-process research and development | - | 0 | 0 | 0 |
| Accounts receivable | 6,647 | 7,753 | 5,630 | -10,029 |
| Prepaid expenses and other current assets | 4,436 | 2,610 | 669 | 986 |
| Inventory | 4,433 | 5,701 | 5,158 | 552 |
| Interest receivable on marketable securities | -24 | -2,242 | 1,543 | 414 |
| Other non-current assets | -3,783 | 145 | 846 | -145 |
| Intangible assets | - | - | - | 8,000 |
| Accounts payable | 12,956 | -5,881 | -7,059 | 16,071 |
| Contract liabilities | 426 | -969 | 4,333 | 4,505 |
| Accrued expenses | -12,319 | 12,604 | 8,581 | -8,835 |
| Net cash provided by (used in) operating activities | 5,069 | -29,733 | -52,889 | -90,805 |
| Cash acquired from anheart acquisition | - | 0 | 0 | 0 |
| Transaction costs related to anheart acquisition | - | 0 | 0 | 0 |
| Purchases of marketable securities | 82,146 | 44,901 | 167,137 | 142,378 |
| Proceeds from sale of marketable securities | 38,558 | 132,073 | 78,528 | 251,689 |
| Cash paid for capitalized market approval intangibles | - | 0 | 8,000 | - |
| Purchases of property and equipment | 48 | 89 | 12 | 253 |
| Net cash (used in) provided by investing activities | -43,636 | 87,083 | -96,621 | 109,058 |
| Proceeds from borrowings, net of issuance costs | - | 11,201 | 0 | 48,901 |
| Payments on borrowings | 0 | 11,199 | 0 | 700 |
| Payments on debt issuance costs | - | 0 | -11 | 6,607 |
| Payments on revenue interest financing agreement | 864 | 0 | 0 | -150,000 |
| Payments on finance agreement | - | 425 | 68 | - |
| Proceeds from issuance of common stock under espp | - | -777 | 0 | -533 |
| Proceeds from exercises of options | 908 | 7,709 | 558 | 1,844 |
| Net cash provided by financing activities | 44 | 8,063 | 501 | 193,971 |
| Effect of foreign exchange rate changes on cash and cash equivalents | -172 | -224 | -64 | 23 |
| Net (decrease) increase in cash and cash equivalents | -38,695 | 65,189 | -149,073 | 212,247 |
| Cash and cash equivalents, beginning of the period | 164,086 | 98,897 | 35,723 | - |
| Cash and cash equivalents, end of the period | 125,391 | 164,086 | 98,897 | - |
Nuvation Bio Inc. (NUVB)
Nuvation Bio Inc. (NUVB)